April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Modulation of Angiogenesis in vitro and in vivo in Ischaemic Retinopathy by Dynepo
Author Affiliations & Notes
  • C. M. McVicar
    Vision Science, Queens University Belfast, Belfast, United Kingdom
  • L. Colhoun
    Vision Science, Queens University Belfast, Belfast, United Kingdom
  • T. Gardiner
    Vision Science, Queens University Belfast, Belfast, United Kingdom
  • C. Kitson
    Vision Science, Queens University Belfast, Belfast, United Kingdom
  • A. Bhatwadekar
    Vision Science, Queens University Belfast, Belfast, United Kingdom
  • R. Medina
    Vision Science, Queens University Belfast, Belfast, United Kingdom
  • A. Stitt
    Vision Science, Queens University Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships  C.M. McVicar, Shire Pharmaceuticals, F; L. Colhoun, None; T. Gardiner, None; C. Kitson, None; A. Bhatwadekar, None; R. Medina, None; A. Stitt, Shire Pharmaceuticals, F.
  • Footnotes
    Support  Shire Pharmaceutical Ltd. and Fight for Sight
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2050. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. M. McVicar, L. Colhoun, T. Gardiner, C. Kitson, A. Bhatwadekar, R. Medina, A. Stitt; Modulation of Angiogenesis in vitro and in vivo in Ischaemic Retinopathy by Dynepo. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2050.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Erythropoietin (EPO) regulates angiogenesis and manufactured EPO analogues (epoetins) may have beneficial properties for microvascular re-modelling following ischaemic injury. In the context of the retina, ischaemia leads to inappropriate neovascularisation and sight-threatening retinopathy. In the current study, we have evaluated the angiogenic activity of human cell-derived epoetin delta (Dynepo) in vitro and also how this analogue regulates various pathogenic end-points in a murine model of ischaemic retinopathy.

Methods: : The angiogenic potential of epoetin delta (concentration range 0.1-100IU/ml) was investigated in vitro using human microvascular endothelial cells. The murine model of oxygen induced retinopathy (OIR) displays central retina ischaemia which drives pre-retinal neovascularisation. Mice received 30-2500IU/Kg of epoetin delta or vehicle control buffer i.p. for 5 concurrent days. On day 5 VEGF and EPO mRNA expression and microglial activation were quantified and the retinal microvascular profile assessed. CD133 and SCA-1 was also assessed in the bone marrow by flow cytometry.

Results: : Epoetin delta caused a significant reduction in in-vitro angiogenic activity when compared to controls (p<0.001) (0.1-1IU/ml) while at higher non pharmacological concentrations (>20IU/ml) there was a significant increase in angiogenesis (p<0.001). Epoetin delta-treatment of mice subjected to OIR induced a significant increase in retinal VEGF (p<0.001) and EPO-R mRNA expression (p<0.05) and attenuated microglial numbers and activation state in comparison to controls (p<0.05). Epoetin delta induced no increase in pre-retinal neovascularisation but induced a significant intra-retinal vessel forming response in the ischaemic regions (p<0.05). Epoetin Delta increased the hematopoetic stem cell markers CD133 and Sca-1.

Conclusions: : Epoetin delta induces a complex angiogenic response in vitro and in vivo. This human cell derived epoetin delta induces significant re-modelling of the ischaemic retina and this suggests a protective role in ischaemic retinopathies.

Keywords: retinal neovascularization • diabetic retinopathy • hypoxia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×